Jazz Pharmaceuticals PLC

Collateral False Claims Act case concerning the '306 patent. Relator alleges Jazz defrauded the PTO in obtaining the '306 patent; the United States and several states declined to intervene, an amended complaint was filed Sept 1, 2024, and Jazz's motion to dismiss was filed Dec 2, 2024, with oral argument Apr 2, 2025.

Indirect purchaser class action by Hollman against Jazz; consolidated into/related to the Xyrem MDL.

Antitrust/pay-for-delay class action listing U.S. 7,895,059 among the listed patents; consolidated in the Xyrem antitrust proceedings.

Antitrust/payor action in N.D. Ill. against Jazz Pharmaceuticals; US 6,780,889 is named among the patents at issue. Terminated on 2020-07-14, consistent with the July 2020 voluntary dismissals of payor suits to pursue claims in the N.D. Cal. MDL.

Antitrust action brought by a Blue Cross/Blue Shield-related plaintiff; the '219 patent appears in the record.

Blue Cross affiliate/related antitrust action terminated July 14, 2020.

Antitrust class action in the Xyrem indirect-purchaser litigation. The '730 patent is cited as an Orange Book REMS patent, and the case was consolidated into the In re Xyrem MDL.

Xyrem antitrust action related to the Xyrem MDL; US 7,765,107 is listed among the patents at issue in the narrative.

Antitrust action in N.D. Cal. against Jazz Pharmaceuticals; the complaint names US 6,780,889 among the patents at issue. The narrative describes it as a payor/indirect-purchaser Xyrem antitrust action.

Antitrust action by Blue Cross and Blue Shield Association against Jazz in N.D. Cal. It cites the '106 patent among patents at issue and was terminated July 15, 2020.

Antitrust/payor action in N.D. Ill. against Jazz Pharmaceuticals; US 6,780,889 is named among the patents at issue. Terminated on 2020-07-15.

Antitrust action in which the '219 patent is listed.

Antitrust case citing the '275 patent; terminated Jul. 15, 2020 by early dismissal and later refiled/consolidated in N.D. Cal.

Antitrust action terminated July 15, 2020, likely transferred to the Xyrem MDL.